72 related articles for article (PubMed ID: 19729180)
21. Safety and immunogenicity of BPV-1 L1 virus-like particles in a dose-escalation vaccination trial in horses.
Hainisch EK; Brandt S; Shafti-Keramat S; Van den Hoven R; Kirnbauer R
Equine Vet J; 2012 Jan; 44(1):107-11. PubMed ID: 21895749
[TBL] [Abstract][Full Text] [Related]
22. Inoculation of young horses with bovine papillomavirus type 1 virions leads to early infection of PBMCs prior to pseudo-sarcoid formation.
Hartl B; Hainisch EK; Shafti-Keramat S; Kirnbauer R; Corteggio A; Borzacchiello G; Tober R; Kainzbauer C; Pratscher B; Brandt S
J Gen Virol; 2011 Oct; 92(Pt 10):2437-2445. PubMed ID: 21715602
[TBL] [Abstract][Full Text] [Related]
23. Papillomavirus prophylactic vaccines: established successes, new approaches.
Campo MS; Roden RB
J Virol; 2010 Feb; 84(3):1214-20. PubMed ID: 19906917
[TBL] [Abstract][Full Text] [Related]
24. Papillomavirus-like Particles in Equine Medicine.
Hainisch EK; Jindra C; Kirnbauer R; Brandt S
Viruses; 2023 Jan; 15(2):. PubMed ID: 36851559
[TBL] [Abstract][Full Text] [Related]
25. Chapter 12: Prophylactic HPV vaccines: underlying mechanisms.
Stanley M; Lowy DR; Frazer I
Vaccine; 2006 Aug; 24 Suppl 3():S3/106-13. PubMed ID: 16949996
[TBL] [Abstract][Full Text] [Related]
26. Bovine papillomavirus type 1 (BPV1) and BPV2 are closely related serotypes.
Shafti-Keramat S; Schellenbacher C; Handisurya A; Christensen N; Reininger B; Brandt S; Kirnbauer R
Virology; 2009 Oct; 393(1):1-6. PubMed ID: 19729180
[TBL] [Abstract][Full Text] [Related]
27. Potential of a BPV1 L1 VLP vaccine to prevent BPV1- or BPV2-induced pseudo-sarcoid formation and safety and immunogenicity of EcPV2 L1 VLPs in horse.
Hainisch EK; Abel-Reichwald H; Shafti-Keramat S; Pratscher B; Corteggio A; Borzacchiello G; Wetzig M; Jindra C; Tichy A; Kirnbauer R; Brandt S
J Gen Virol; 2017 Feb; 98(2):230-241. PubMed ID: 28284277
[TBL] [Abstract][Full Text] [Related]
28. Type-specific L1 virus-like particle-mediated protection of horses from experimental bovine papillomavirus 1-induced pseudo-sarcoid formation is long-lasting.
Harnacker J; Hainisch EK; Shafti-Keramat S; Kirnbauer R; Brandt S
J Gen Virol; 2017 Jun; 98(6):1329-1333. PubMed ID: 28635592
[TBL] [Abstract][Full Text] [Related]
29. A papillomavirus-like particle (VLP) vaccine displaying HPV16 L2 epitopes induces cross-neutralizing antibodies to HPV11.
Slupetzky K; Gambhira R; Culp TD; Shafti-Keramat S; Schellenbacher C; Christensen ND; Roden RB; Kirnbauer R
Vaccine; 2007 Mar; 25(11):2001-10. PubMed ID: 17239496
[TBL] [Abstract][Full Text] [Related]
30. A multimeric L2 vaccine for prevention of animal papillomavirus infections.
Jagu S; Malandro N; Kwak K; Yuan H; Schlegel R; Palmer KE; Huh WK; Campo MS; Roden RB
Virology; 2011 Nov; 420(1):43-50. PubMed ID: 21920572
[TBL] [Abstract][Full Text] [Related]
31. Genomic sequences of bovine papillomaviruses in formalin-fixed sarcoids from Australian horses revealed by polymerase chain reaction.
Bloch N; Breen M; Spradbrow PB
Vet Microbiol; 1994 Jul; 41(1-2):163-72. PubMed ID: 7801519
[TBL] [Abstract][Full Text] [Related]
32. The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years.
Brown DR; Kjaer SK; Sigurdsson K; Iversen OE; Hernandez-Avila M; Wheeler CM; Perez G; Koutsky LA; Tay EH; Garcia P; Ault KA; Garland SM; Leodolter S; Olsson SE; Tang GW; Ferris DG; Paavonen J; Steben M; Bosch FX; Dillner J; Joura EA; Kurman RJ; Majewski S; Muñoz N; Myers ER; Villa LL; Taddeo FJ; Roberts C; Tadesse A; Bryan J; Lupinacci LC; Giacoletti KE; Sings HL; James M; Hesley TM; Barr E
J Infect Dis; 2009 Apr; 199(7):926-35. PubMed ID: 19236279
[TBL] [Abstract][Full Text] [Related]
33. The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in sexually active women aged 16-26 years.
Wheeler CM; Kjaer SK; Sigurdsson K; Iversen OE; Hernandez-Avila M; Perez G; Brown DR; Koutsky LA; Tay EH; García P; Ault KA; Garland SM; Leodolter S; Olsson SE; Tang GW; Ferris DG; Paavonen J; Steben M; Bosch FX; Dillner J; Joura EA; Kurman RJ; Majewski S; Muñoz N; Myers ER; Villa LL; Taddeo FJ; Roberts C; Tadesse A; Bryan J; Lupinacci LC; Giacoletti KE; James M; Vuocolo S; Hesley TM; Barr E
J Infect Dis; 2009 Apr; 199(7):936-44. PubMed ID: 19236277
[TBL] [Abstract][Full Text] [Related]
34. Interaction of human papillomaviruses with the host immune system: a well evolved relationship.
Frazer IH
Virology; 2009 Feb; 384(2):410-4. PubMed ID: 18986661
[TBL] [Abstract][Full Text] [Related]
35. Bovine papillomaviruses: their role in the aetiology of cutaneous tumours of bovids and equids.
Nasir L; Campo MS
Vet Dermatol; 2008 Oct; 19(5):243-54. PubMed ID: 18927950
[TBL] [Abstract][Full Text] [Related]
36. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial.
Paavonen J; Jenkins D; Bosch FX; Naud P; Salmerón J; Wheeler CM; Chow SN; Apter DL; Kitchener HC; Castellsague X; de Carvalho NS; Skinner SR; Harper DM; Hedrick JA; Jaisamrarn U; Limson GA; Dionne M; Quint W; Spiessens B; Peeters P; Struyf F; Wieting SL; Lehtinen MO; Dubin G;
Lancet; 2007 Jun; 369(9580):2161-2170. PubMed ID: 17602732
[TBL] [Abstract][Full Text] [Related]
37.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
38.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
